U.S. markets open in 5 hours 56 minutes

Theralink Technologies, Inc. (OBMP)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.30000.0000 (0.00%)
At close: 2:32PM EDT
Sign in to post a message.
  • r
    roland
    Where are my sup-dup bagholders at??
  • B
    BayRa
    What happen to OBMP's cancer vaccination technology when it combined to form Theralink?
  • S
    Sam
    I just saw someone post on Twitter that this company is in talks for a potential buyout. Anyone else hear?
  • j
    jeff
    If there was a grant awarded it is not the one everyone here has posted. That was a defense grant for 5.3 mil.that ran from 2006-2016 for their phase 1. I also noticed the 5 knuckle heads that run the company each took 3,000,000 in options at .013 last week. Do you think all of them still have those shares? there was an aweful lot of volume yesterday.
  • K
    Kenneth
    April 16th presentation at AACR Annual Meeting!
  • R
    Robert F. Sawart II
    FDA approved for 60 men for new trails. I believe this is why price has been going as high as 0.040. I bought in at 0.0167. I been seeing recommend a Buy and Hold.
  • B
    BayRa
    It has been reported that OBMP will receive an approximate $5.3 million government grant to continue their mission.
  • B
    BayRa
    I am happy to learn of Robert Holcomb's appointment to OBMP's board. His experience and dedication will be a plus.
  • K
    Kenneth
    I was just reading that the PROVAX Cancer Vaccine by OBMP if successful would generate eight hundred million to one billion three hundred million in revenue according to estimates per year. The net would be roughly nine hundred million. While we are a far cry from anything like that especially since the testing doesn't start until December 17th at Beth Israel Hospital Center I remember years ago a similar company called Amgen was testing a product that ended up being very successful in the market.
  • B
    Bob
    @Brian do you have a personal view on when you expect OBMP to start heading up. Do you think there may be a shift upwards in the latter part of the year with some kind of news in regards to phase 2 coming to light. Or any other date or month you estimate to be worth waiting for. Thanks
  • k
    kevin
    I wish we could get some news about the phasell study
  • B
    Brian
    BATON ROUGE, La., March 22, 2018-- OncBioMune Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted ...
    BATON ROUGE, La., March 22, 2018-- OncBioMune Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted ...
    finance.yahoo.com
  • D
    Daniel
    I had a dream last night about talking to a CPA and he showed me two stocks that would fund my retirement.... this was one of them! Maybe? Perhaps I had better get buying!
  • A
    A
    Volume going through the roofs!!!!
  • F
    Francis
    I see they filed the NT 10-k yesterday. Notice of intent to file the 10-k late, like they always do. Guess the 10-k will be coming soon, not that I'm terribly excited to see it...
  • D
    Deacon
    This should be at least a 40 cent stock just on their huge Mexico potential . 6 cents is a gift.
  • K
    Kenneth
    Note that Provax is in testing at Beth Israel Hospital Center. Any unusual volume could very well indicate trials are going well. At that point it definitely would be worth buying.
  • J
    JOHN
    This company needs to share some news with the investor. Did 1, 2, 3 people sign up for the study. give us an update
  • j
    jeff
    The price per share has everything to do with this company's health. They just defaulted on another note this past quarter for 200k resulting in the release of millions of shares at .05. Total shares out used to be about 135 million a few months ago now its at 152 million. Although it is common for small pharma companies to issue blocks of stock to raise capital from time to time to get through trials it usually comes with an announcement at offering and a projection of how far those funds should them. Out of all the companies I have been involved with as a shareholder this one has the worst management . This CFO needs to be removed. In the past year he was paid 200k for letting the stock lose over 80% of its value. He hasn't secured any decent finance options or partnerships that have been announced. I think as shareholders we should all call the company directly asking that the CEO make statements addressing these issues. He needs to act like he is in charge and address we the shareholders on how he intends to move "our" company forward.
  • B
    BayRa
    OBMP on February 21, 2019, filed a schedule 14C report to increase the number of shares from 500 million to 1.5 trillion shares. They needed 50% approval of stockholders which they obtained by using shares from the Board, Officers, and friends. They rationalized the increase in shares based upon their future financial needs.
    We can only guess that they need financial backing to complete the phase 2 trials for the prostate vaccine. In addition, they may be preparing Phase 1 trials for their other cancer-fighting vaccines. One other possibility is they need the shares for a potential buy-in by another company with deep pockets.
    In any case, the time horizon for OBMP’s financial development has just been extended. They indicated that all stocks holders of record would be sent an adversary relative to the Schedule 14C filing.
    I am a firm believer in the technology OBMP has developed. In the past, I have met Dr. Brain Barnett and Dr. Robert Elliott. They are both fine individuals and I have high hopes that OBMP will be successful. For the time being, we all must be patient and hopeful.